These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31795214)

  • 41. Structural basis for the inhibition of Polo-like kinase 1.
    Xu J; Shen C; Wang T; Quan J
    Nat Struct Mol Biol; 2013 Sep; 20(9):1047-53. PubMed ID: 23893132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
    Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
    Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
    Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of potential Plk1 targets in a cell-cycle specific proteome through structural dynamics of kinase and Polo box-mediated interactions.
    Bibi N; Parveen Z; Rashid S
    PLoS One; 2013; 8(8):e70843. PubMed ID: 23967120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
    J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
    Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors.
    Lu S; Liu HC; Chen YD; Yuan HL; Sun SL; Gao YP; Yang P; Zhang L; Lu T
    Int J Mol Sci; 2011; 12(12):8713-39. PubMed ID: 22272100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Sun H; Xu L; Jiang C
    Bioorg Chem; 2019 Oct; 91():103148. PubMed ID: 31376784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.
    Liu S; Yosief HO; Dai L; Huang H; Dhawan G; Zhang X; Muthengi AM; Roberts J; Buckley DL; Perry JA; Wu L; Bradner JE; Qi J; Zhang W
    J Med Chem; 2018 Sep; 61(17):7785-7795. PubMed ID: 30125504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
    Fu Z; Su M; Liu X; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.
    Narvaez AJ; Ber S; Crooks A; Emery A; Hardwick B; Guarino Almeida E; Huggins DJ; Perera D; Roberts-Thomson M; Azzarelli R; Hood FE; Prior IA; Walker DW; Boyce R; Boyle RG; Barker SP; Torrance CJ; McKenzie GJ; Venkitaraman AR
    Cell Chem Biol; 2017 Aug; 24(8):1017-1028.e7. PubMed ID: 28807782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rational Molecular Design of Potent PLK1 PBD Domain-binding Phosphopeptides Using Preferential Amino Acid Building Blocks.
    Mao XL; Wang KF; Zhu F; Pan ZH; Wu GM; Zhu HY
    Chem Biodivers; 2016 Aug; 13(8):1103-10. PubMed ID: 27450535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds.
    Abdelfatah S; Fleischer E; Klinger A; Wong VKW; Efferth T
    Invest New Drugs; 2020 Feb; 38(1):1-9. PubMed ID: 30877426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1.
    Alverez CN; Park JE; Toti KS; Xia Y; Krausz KW; Rai G; Bang JK; Gonzalez FJ; Jacobson KA; Lee KS
    J Med Chem; 2020 Nov; 63(22):14087-14117. PubMed ID: 33175530
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
    Huggins DJ; McKenzie GJ; Robinson DD; Narváez AJ; Hardwick B; Roberts-Thomson M; Venkitaraman AR; Grant GH; Payne MC
    PLoS Comput Biol; 2010 Aug; 6(8):. PubMed ID: 20711360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
    Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
    Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.